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A B S T R A C T
Purpose: Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disorder in the western
world. The involvement of the central nervous system (CNS) or the optic nerve in CLL, however, is rare. We
report a case of a previously untreated patient with CLL whose first manifestation of the disease was a pro-
gressive visual loss caused by optic neuropathy.
Observations: Clinical manifestations, optical coherence tomography (OCT), and automated visual fields pointed
to the diagnosis of neuropathy. Leukemic involvement of the CNS was confirmed after cells suggestive of CLL
were found by cerebrospinal fluid analysis. Optic nerve infiltration is thought to be the cause of this optic
neuropathy, and the clinical course and treatment are described herein.
Conclusions: When readily diagnosed, optic nerve infiltration is a rare, yet manageable complication of CLL.
1. Introduction
Chronic lymphocytic leukemia (CLL) is the most common lympho-
proliferative disorder in the western world, with an annual incidence of
3:100 000.1–5 It is usually an indolent disease, and most patients are
diagnosed in the early stages (Binet A, Rai 0/1).4,6 CLL more commonly
affects the elderly and is most frequently diagnosed in the 7th and 8th
decades of life, with a male predominance (2:1).1,4,5 The median sur-
vival is approximately six years, with infections being the most frequent
complication of CLL and a common cause of death.5–7
Clinically, involvement of the central nervous system (CNS) in CLL
is rare, with an incidence rate ranging from 0.8 to 2% in antemortem
studies.1–4,7 However, autopsy studies reveal that, even in asympto-
matic patients, the incidence of infiltration of the brain, meninges, or
spinal cord is high (8–71%).1–4,7 The most cited CNS manifestations of
CLL include cognitive and cerebellar dysfunction and cranial nerve
palsies; however, optic nerve involvement remains rare, which may
explain why it is seldom considered in the differential diagnosis of vi-
sual loss in CLL.1,3,4,8 In leukemias, CNS involvement usually develops
in the final stages of the disease.8 In CLL, however, this may not be the
case, as Rai stage, duration of CLL, immunologic phenotype, or
peripheral white blood cell (WBC) count are not symptomatic of CNS
involvement.4
To our knowledge, few cases of optic nerve infiltration in CLL have
been described.1–4,7–11 Although uncommon, knowledge of diagnostic
criteria for this condition is imperative, as permanent blindness can
occur if CLL is left undiagnosed and untreated. We report a rare clinical
case with good supporting facts of a progressive visual loss caused by
optic neuropathy in a previously untreated patient with CLL diagnosed
two years ago.
2. Case report
A 48-year-old man presented with a 2-week history of vision loss in
the left eye with mild retrobulbar discomfort and dyschromatopsia. The
patient had been diagnosed with CLL two years prior (FISH with
trisomy 12). Diagnosis was conferred after a thorough investigation
following a change in WBC during a routine check-up. The patient did
not require treatment for CLL and remained asymptomatic. He had a
body mass index of 28.86 kg/m2 and was under chronic treatment for
arterial hypertension and dyslipidemia with telmisartan and pitavas-
tatin, respectively.
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Upon examination, best corrected visual acuity (BCVA) was 10/10
for the right eye (OD) and finger counting at 30 cm for the left eye (OS),
with a left relative afferent pupillary defect. Slit lamp biomicroscopy,
intraocular pressures, and ocular motility were normal. Fundoscopy
was normal in OD, and revealed generalized optic disc edema in OS.
Automated visual field testing was normal for OD and showed central/
cecocentral scotoma in OS (Fig. 1). Optical coherence tomography
(OCT) displayed a normal retinal nerve fiber layer (RNFL) thickness of
optic nerve in OD, and was increased in all sectors in OS, compatible
with optic disc edema (Fig. 2). Macular OCT was normal in both eyes;
after automatic retinal segmentation, the thickness of ganglion cell
layers from OD and OS were compared and found to be similar. Brain
magnetic resonance imaging showed T2 enlarged thickness of the ca-
liber of the optic nerve in OS (Fig. 3). Initial lumbar puncture revealed
an opening pressure of 13 cmH2O. Cerebrospinal fluid (CSF) analysis
revealed no evidence of microorganisms, but a pathological monoclonal
population of B cells was found. The immunophenotype of this popu-
lation was CD19+, CD20+, CD5+, CD38−, and CD45+, suggestive of
CLL cells present in CSF. These results were confirmed with a second
CSF analysis days later.
Complete blood count revealed a hemoglobin of 15.7 g/dL (normal:
13–17 g/dL), 18,000 WBC/mL (normal: 4,500−11,000 WBC/mL) with
67% lymphocytes and platelets count of 179 × 103. Leukocyte mor-
phology was compatible with a chronic lymphoproliferative syndrome.
Remaining analytical evaluation was normal, including serology for
common infectious and immunologic diseases.
The patient began treatment with high doses of intravenous me-
thylprednisolone (five days, 1,000 mg/day). After three weeks, he had
no ocular pain, considerable improvement in dyschromatopsia, and a
BCVA of 10/10 and 8/10 in OD and OS, respectively. The ophthalmo-
scopy of the left eye revealed a slight generalized pallor of the left optic
disc. Visual field testing was normal in both eyes. In the OS OCT, there
was a reduction of RNFL thickness reaching nearly normal values, in-
dicating a reduction in the swelling of this layer (Fig. 4). Automatic
retinal segmentation was repeated, revealing that ganglion cell layer
thickness of OS was decreased relative to OD and relative to OS at the
onset, possibly indicating atrophy of this layer (Fig. 5). Total macular
retina thickness of OS was also decreased relative to OD, and to OS at
the onset. Practically all the variability in the total retina thickness of
OS was attributable to the change in the ganglion cell layer.
The patient was started on four cycles of intrathecal therapy (IT)
with dexamethasone and methotrexate. One month after the last IT
cycle (i.e., four months after the onset), no complications from the
treatment were found. Automated visual field testing was normal and
RNFL OCT was within normal limits. CSF analysis was repeated and
cells suggestive of CLLs remained present. At this point, ibrutinib is
being considered to be initiated.
The analysis of the mitochondrial DNA sequences of MT-ND1, MT-
ND4, and MT-ND6 was also performed. The most common mutations
were not found, but in MT-ND1, the m.4216T > C variant was pre-
sent, which is associated with Leber hereditary optic neuropathy
(LHON) phenotype of unclarified pathogenicity.
3. Discussion
Optic neuropathy in patients with CLL is a challenge. There is an
extensive differential diagnosis, with more common considerations
being inflammatory disorders such as sarcoidosis and opportunistic
Fig. 1. Automated visual fields testing of both eyes (at onset).
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Fig. 2. Optical coherence tomography (OCT): retinal nerve fiber layer (RNFL) map of both eyes (at onset).
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infections by fungi, parasites, viruses, and bacteria11; these diagnoses
were excluded by thorough blood and CSF analyses.
The conclusive diagnosis of CLL nerve infiltration requires a nerve
biopsy.11 In most cases, biopsy of the optic nerve is discouraged given
its high risk of damage. For this reason, and considering the positive
response to the initial methylprednisolone treatment, this diagnostic
method was not used.1,11 Although not definitive, CSF analysis by flow
cytometry can be helpful for diagnosis by identifying malignant lym-
phocytes, as was the case with our patient.1,11 Flow cytometry should
always be used because it significantly increases the detection rate of
malignant cells in the CSF and can differentiate a polyclonal reactive B-
cell population from a monoclonal malignant population.7 CSF analysis
is also essential to eliminate the possibility of opportunistic infections of
the CNS, which can be presented in a similar way.1,3
Optic nerve infiltration by CLL cells that causes optic neuropathy is
a rare but devastating condition that can lead to permanent blindness if
left undiagnosed and untreated.1,3,11 In this case, optic neuropathy was
the first clinical manifestation of a previously asymptomatic CLL. Pre-
vious studies suggest that this may indicate a clinical worsening of the
CLL.8 CNS symptoms could signal the first manifestation of a more
malignant variant arising from a dedifferentiation of the underlying
CLL.7
The mechanism by which CNS is infiltrated in CLL remains un-
known1,4,7; however, many theories have been hypothesized: leukemia
cells may (1) reach the CNS from sporadic intracranial petechial he-
morrhages; (2) migrate across perforating vessels into the subarachnoid
space; (3) direct extension from seeded meninges into CSF; or (4)
spread through perineural sheaths on cranial nerves.1,4,7,12
Although inferred from other types of leukemias, three factors have
been associated with CNS involvement in CLL: transformation into a
more aggressive variant of CLL (Richter syndrome), thrombocytopenia,
and a T-cell variant.3,8,12 Patients with thrombocytopenia may be more
likely to have small hemorrhages in the CNS, spreading leukemia cells
at this site.12 None of these factors were present in our patient.
When optic nerve infiltration symptomatology includes visual
changes, rapid and aggressive treatment is thought to be most effective
to prevent more widespread loss of nerve fibers.8 Classically, patients
with this diagnosis underwent orbital irradiation with considerable
clinical improvement; in more recent years, however, intrathecal
methotrexate without irradiation has been used to positive effect.3,8
Ibrutinib, a Bruton tyrosine kinase inhibitor, has also been used with
methotrexate with positive results.1 This drug is often considered in
patients with CLL who present neurological symptoms.2
CSF analysis post-treatment might be important. Studies show that
patients who achieved CSF clearance after treatment were less likely to
experience a relapse in their neurologic symptoms, although neurologic
resolution can be achieved even in the setting of persistently positive
CSF.7
The study of optic neuropathies is always demanding. This case
highlights the need to never ignore optic nerve infiltration by CLL, even
in patients who were previously asymptomatic and whose conditions
were apparently controlled. CSF analysis is an invaluable tool that was
crucial in this diagnosis, and it should always be considered when a
patient with CLL develops symptoms of optic neuropathy. A timely
diagnosis can be extremely important; not only could it spare the pa-
tient's vision, but it could also detect an underlying disease with
prognostic implications.
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Fig. 3. Brain magnetic resonance imaging at onset.
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Fig. 4. Optical coherence tomography (OCT): retinal nerve fiber layer (RNFL) map of both eyes three weeks after onset.
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Fig. 5. Ganglion cell layer thickness analysis of both eyes at onset and three weeks later.
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